To investigate whether curative prostate cancer (PCa) treatment was received less often by men with both PCa and Type 2 diabetes mellitus (T2DM) as little is known about the influence of T2DM diagnosis on the receipt of such treatment in men with localized PCa.
Introduction
Prostate cancer (PCa) is the most common cancer in men in Europe, with~417 000 new cases diagnosed in 2012 [1] . Incidence is strongly related to age, and~36% of cases are diagnosed in men aged ≥75 years, with a peak incidence at between age 75 and 79 years [2] . More than 60 million people have been diagnosed with type 2 diabetes mellitus (T2DM) across Europe, and it is estimated that >10% of men in Europe have T2DM [3] . As a result, these two increasingly prevalent conditions often occur together in the same men; however, the relationship is more complex than just two prevalent conditions co-existing. T2DM is included in the cluster of disorders that comprise metabolic syndrome [4] . During the last decade, studies have investigated whether metabolic syndrome is involved in the aetiology of PCa [5] [6] [7] . A meta-analysis to quantify the risk of PCa related to metabolic syndrome found a pooled relative risk of 1.54 (95% CI 1.23-1.94) [4] . Recent studies have also suggested that the presence of metabolic syndrome or some of its features is associated with higher-grade disease in men with PCa, and can lead to more rapid progression to castrate-resistant PCa [8, 9] .
Men with untreated localized PCa have different life expectancy depending on their comorbidities [10] . A Canadian case-cohort study of 630 men studied the impact of specific comorbid conditions on death within 10 years in men with localized PCa [11] . Respiratory and cardiovascular diseases (CVDs) were the most common conditions and were most strongly associated with an increased risk of death. Pharmacologically treated T2DM was present in 7% of the men at the time of PCa diagnosis and was associated with a 35% higher risk of death from other causes than PCa at 10 years. The association between components of the Charlson comorbidity index (CCI) on mortality after radical prostatectomy (RP) has also been studied. Eight conditions were significant predictors of overall mortality, including diabetes [12] . T2DM may therefore be associated with a shorter life expectancy in men with PCa.
As a result of the association between comorbidities and life expectancy in men with localized PCa [10, 12, 13] , current PCa treatment guidelines recommend that a man should have a life expectancy of ≥10 years in order for curative treatment to be indicated [14] .
Given the above, we used data from PCBaSe Sweden to investigate if a diagnosis of T2DM decreased the probability of curative treatment in men with localized PCa and how this was associated with PCa-specific and all-cause mortality.
Study Population and Methods

Study Population and Data Collection
PCBaSe Sweden 3.0 is based on the National Prostate Cancer Register of Sweden (NPCR), which became nationwide in 1998 and covers 98% of all newly diagnosed cases of PCa, as compared with the Swedish Cancer Register [15, 16] . The NPCR includes information on date of diagnosis, age at diagnosis, tumour stage and differentiation, and serum levels of PSA at time of diagnosis. Risk categories were determined according to a modified version of the National Comprehensive Cancer Network guidelines [17] as follows: low risk: local clinical stage T1-2, Gleason score 2-6 and PSA <10 ng/mL; intermediate risk: T1-2, Gleason score 7 and/or PSA 10-20 ng/mL; high risk: T3 and/or Gleason score 8-10 and/or PSA 20-50 ng/mL; regionally metastatic/locally advanced: T4 and/or N1 and/or PSA 50-100 ng/mL in the absence of distant metastases (M0 or MX); and distant metastases: M1 and/or PSA >100 ng/ mL. Using the Swedish personal identity number, five PCafree men from the general population in Sweden were randomly selected within sets of men who matched each index case on birth year and county of residence, and were included in a PCa-free control cohort [15] . Both men with PCa and those in the control cohort were subsequently linked to a series of national healthcare registers and demographic databases, to obtain data on comorbidity, socio-economic status, and cause of death, including the National Diabetes Register.
PCBaSe
traject includes all of the data in PCBaSe 3.0, but has additional linkages. It focuses specifically on men diagnosed with PCa between 1992 and 2012 with available information on their complete treatment trajectory [16] . The main outcome variable for this study, treatment with RP and RT, was retrieved from PCBaSe traject , which represents actual treatment received, not just intended primary treatment. We looked only at primary treatment, i.e. first definitive treatment received after PCa diagnosis, and not subsequent treatments. The main exposure variable for the present study, T2DM, was defined as receiving two or more consecutive prescriptions for an antidiabetic drug within 6 months. Information on filled prescriptions of metformin, sulphonylurea and insulin was obtained from the National Prescribed Drug Register using Anatomical Therapeutic Chemical (ATC) classification codes (insulin: ANA; metformin: A10BA/BD; sulphonylurea:A10BB) [18] . Fewer than 2% of those with T2DM received prescriptions for alternative oral hypoglycaemic drugs; in the present analysis these people were considered in the metformin group. We did not exclude those with type 1 diabetes receiving insulin prescriptions, however, these cases were few. Comorbidities were measured according to the CCI, which assigns weights to a number of medical conditions, including diabetes and hypertension, based on discharge diagnoses in the Patient Register [13] . We excluded diabetes from the CCI score. Each condition was assigned a score of 1, 2, 3 or 6, and the final CCI was the sum of these scores. Individuals were grouped into CCI categories for final scores of 0, 1, 2 or ≥3. Information on age at diagnosis, T stage, Gleason score, PSA at diagnosis, proportion of cores with cancer, mode of detection of PCa, education and marital status was also used. For men with missing data on Gleason score (0.7%), we applied multivariate imputation using chained equations (MICE), also known as imputation, using fully conditional specifications [19] . The MICE method imputes multiple variables sequentially using univariate fully conditional specifications. 
Analysis
We used multivariate logistic regression to calculate odds ratios (ORs) for receiving curative treatment in men with and without T2DM (as defined above). The analysis was adjusted for age, T-stage, Gleason score, proportion of cores with cancer, CCI (excluding diabetes), mode of detection, education and marital status. When adjusting for PSA, linear splines with knots at 3, 10 and 20 were used.
We then performed an analysis to evaluate how an additional diagnosis of hypertension, dyslipidaemia or CVD, as compared with only T2DM, affected the association between T2DM and curative treatment. We used ATC codes for the following prescriptions from the Prescribed Drug Register to assess these additional diagnoses: statins (C10), antihypertensive medication (C02) and anti-coagulants (B01).
To evaluate the association of PCa and T2DM with survival, we created a comparison cohort including men with only T2DM from the PCa-free cohort. First, we selected all index cases (PCa and T2DM, as registered with a date of diagnosis from the National Diabetes Register). Controls in the comparison cohort were matched with these index cases on age (AE 1 year), duration of T2DM and type of T2DM treatment (insulin vs oral drugs). For each index case we selected five control subjects in each comparison cohort. Overall survival for up to 8 years of follow-up was then calculated for men in the comparison cohort and for men with T2DM and PCa who did and did not receive curative treatment. The 8-year survival probabilities were assessed because data were only available for the period 2006-2014. Finally, we calculated the cumulative incidence of PCa-specific death and death from other causes in those who did and did not receive curative treatment.
All data management was performed with SAS version 9.3 (SAS Institute, Cary, NC, USA) and all data analysis was conducted using R version 2.13.2 (R Foundation for Statistical Computing, Vienna, Austria).
Results
A total of 2210 men with PCa and T2DM and 23 071 men with PCa only were included in the analysis. Of those with T2DM, 916 were treated with insulin and 1537 with metformin (Table 1) . Men with T2DM were older than those without T2DM; only 6% of men with T2DM were aged <60 years, compared with 13% of men with no diabetes (Table 1) . Men with T2DM also had a higher CCI score and were more likely to have high-risk than intermediate-risk PCA than men without T2DM (Table 1) . Those with T2DM were also more likely to have a Gleason score >8, a higher proportion of cores with cancer and PSA >20 ng/mL ( Men with other comorbidities (based on additional filled prescriptions for drugs for hypertension, dyslipidaemia or CVD) in addition to T2DM had virtually the same probability of curative treatment for PCa: men with T2DM only (OR 0.78; 95% CI 0.69-0.88), men with T2DM and dyslipidaemia (OR 0.79; 95% CI 0.69-0.90), and men with T2DM and CVD (OR 0.75; 95% CI 0.60-0.93 [ Table 3 ]).
The 8-year overall survival was lower in PCa-free men with T2DM compared with men with T2DM and PCa who received curative treatment. At 8-year follow-up, the survival was 73% for men with T2DM and no PCa, 79% for men with T2DM and high-risk PCa who received curative treatment, and 33% for men with T2DM and high-risk PCa who did not receive curative treatment (Fig. 1) . The corresponding survival rates for intermediate-risk PCa were 77%, 86% and 55%. The cumulative incidence of death from PCa was low in both intermediate-and high-risk PCa groups when curative treatment was received. In men with intermediate-risk PCa who were not curatively treated, the cumulative incidence of PCa-specific death remained low at 8-year follow-up, whilst the cumulative incidence of death from other causes was much higher; however, in men with high-risk PCa, the cumulative incidence of PCa-specific death contributed to a much greater proportion of the overall death rate in those not treated curatively (Fig. 2 ).
Discussion
Men with T2DM were less likely to receive curative treatment for localized PCa, particularly those receiving insulin. While men with T2DM and high-risk PCa who did receive curative treatment had a substantially higher survival rate than men with T2DM and PCa who were conservatively treated, those selected for curative treatment were found to be the healthiest patients.
Comorbidities affect 10-year mortality more than PCa-specific mortality in men with conservatively treated localized PCa [10] [11] [12] , which has led to the recommendation that men have a life expectancy of ≥10 years in order for curative treatment to be indicated [14] . It is difficult to predict an individual's 10-year life expectancy, however, and none of the existing nomograms that help calculate this are currently widely used in clinical practice [20] .
The impact of comorbidity and age on treatment and survival in men with PCa has been investigated in a Dutch study of >6000 men [21] . The proportion of men aged 60-69 years who underwent RP decreased significantly, from 32% of men without comorbidity to 17% of men with two or more comorbid conditions. This proportion decreased further, from 8% to 3%, in those aged 70-79 years. A previous study using data from PCBaSe showed that as CCI score increased, men were more likely to receive RT than RP [22] . The present study findings are in line with these observations, even after taking into account a wide range of potential confounders (age, comorbidities and cancer characteristics).
Nevertheless, to interpret the present findings, it is important to evaluate life expectancy as outlined in the guidelines for PCa treatment [14] . The life expectancy of a Swedish man at age 65 is 19 years [23] , with similar figures seen across Europe [23] . T2DM decreases life expectancy by up to 10 years [24] ; however, men with PCa and T2DM who received curative treatment in the present study had substantially higher overall survival rates than men with T2DM and PCa who received conservative treatment. The ADT, androgen deprivation therapy; CCI, Charlson comorbidity index; PCa, prostate cancer; RP, radical prostatectomy; RT, radiotherapy; T2DM, type 2 diabetes mellitus. *Risk groups according to modification of the National Comprehensive Cancer Network Practice Guidelines [17] .
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© 2017 The Authors BJU International © 2017 BJU International selection of the healthiest men and allocation to curative treatment among men with T2DM and PCa was indicated by the fact that these men had a better overall survival than corresponding PCa-free men with T2DM (Fig. 1) . The selection of healthy men for curative treatment is also highlighted by the lower 90-day mortality after RP compared with the background population in a previous Swedish study [25] . Williams and Huo [26] have also demonstrated this selection bias, showing a survival advantage in men receiving both RP and RT vs a PCafree comparison cohort. This selection was also reflected in the present study in PCa-specific mortality (Fig. 2) , which remained low regardless of PCa treatment for intermediate-risk disease. The higher proportion of death from other causes in men not curatively treated confirms that these men have high comorbidity with ensuing increased risk of death from competing causes. In men with conservatively treated high-risk PCa, however, 22% died from PCa within 8 years of diagnosis, suggesting that a larger proportion of these men should have received curative treatment. In the present study, we also show that men with T2DM were more likely to receive primary androgen deprivation therapy than those without T2DM (25% vs 15% [ Table 1 ]). Given the metabolic and cardiovascular side effects of androgen deprivation therapy, this is another reason to ensure that men with PCa and T2DM are not undertreated with respect to curative treatment.
The strengths of the present study include its large size, the population-based design and the comparison cohort of PCafree men with T2DM. Furthermore, we had access to data from a number of nationwide population-based high-quality registers, including the Prescribed Drug Register, the Inpatient Register, the Cause of Death Register and the National Diabetes Register. Limitations include the fact that we only had 8 years of follow-up data instead of the conventional 10-year survival curves or estimated life expectancies. A further limitation is that, by using drug prescriptions as a proxy for T2DM, we would have missed all T2DM cases treated by diet alone; however, diet-controlled T2DM is unlikely to have influenced PCa treatment decisions. We show that, in fact, it was only those treated with insulin who were less likely to receive curative treatment. As discussed above, we acknowledge that a selection bias of the healthiest men to receive curative treatment among men with T2DM and PCa exists. This was indicated by the fact that these men had better overall survival times than corresponding PCa-free men with T2DM. Confounding by indication may also have influenced selection for curative treatment, i.e. those with the most favourable prognosis may have preferentially been chosen for curative treatment. By adjusting for tumour characteristics we have accounted for this as much as possible; however, as with all observational data, there may be some residual confounding.
In conclusion, men with T2DM were less likely to receive curative treatment for localized PCa. Men with T2DM and high-risk PCa who received curative treatment had 
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© 2017 The Authors BJU International © 2017 BJU International substantially higher survival rates than men with T2DM and PCa who were conservatively treated. Some of the survival differences represent a selection bias of the healthiest patients to receive curative treatment, but of the men with conservatively treated high-risk PCa, 22% died specifically from PCa, suggesting that a larger proportion of these men should have received curative treatment. Clinicians should interpret these data carefully and ensure that individual patients with T2DM and PCa are not under-nor overtreated. 
